Atara Biotherapeutics Inc
Buy, Hold or Sell?

Let's analyse Atara Biotherapeutics Inc together

Penke I guess you are interested in Atara Biotherapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Atara Biotherapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Atara Biotherapeutics Inc

I send you an email if I find something interesting about Atara Biotherapeutics Inc.

Quick analysis of Atara Biotherapeutics Inc (30 sec.)

1. Valuation of Atara Biotherapeutics Inc (5 min.)

Live pricePrice per share (EOD)

$1.88

Book Value per Share

$1.23

2. Growth of Atara Biotherapeutics Inc (5 min.)

Is Atara Biotherapeutics Inc growing?

	Current year	Previous year	Grow	Grow %
How rich?	$126.6m	$330m	-$131.1m	-66.0%

How much money is Atara Biotherapeutics Inc making?

	Current year	Previous year	Grow	Grow %
Making money	-$57m	-$85m	$27.9m	?
Net Profit Margin	-9,199.0%	-1,796.0%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Atara Biotherapeutics Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#381 / 1215

Most Revenue
#246 / 1215

Most Profit
#1090 / 1215

Most Efficient
#1110 / 1215

Fundamentals of Atara Biotherapeutics Inc

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

1.1. Profitability of Atara Biotherapeutics Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Atara Biotherapeutics Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
A Net Profit Margin of -33,743.0% means that $-337.43 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Atara Biotherapeutics Inc:

The MRQ is -33,743.0%. The company is making a huge loss. -2
The TTM is -9,199.0%. The company is making a huge loss. -2

Trends

Current period		Compared to		+/-
MRQ	-33,743.0%	TTM	-9,199.0%	-24,544.0%
TTM	-9,199.0%	YOY	-1,796.0%	-7,403.0%
TTM	-9,199.0%	5Y	-2,199.0%	-7,000.0%
5Y	-2,199.0%	10Y	-1,188.6%	-1,010.4%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-33,743.0%	-194.7%	-33,548.3%
TTM	-9,199.0%	-273.6%	-8,925.4%
YOY	-1,796.0%	-315.2%	-1,480.8%
5Y	-2,199.0%	-539.0%	-1,660.0%
10Y	-1,188.6%	-664.9%	-523.7%

Measures how much net profit Atara Biotherapeutics Inc earns for each $1 of revenue.

Revenue is the amount of profit Atara Biotherapeutics Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Atara Biotherapeutics Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Atara Biotherapeutics Inc makes more profit. This shows the investor how efficiently Atara Biotherapeutics Inc is operating in general and compared to other companies in the same industry. Atara Biotherapeutics Inc operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Atara Biotherapeutics Inc. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Atara Biotherapeutics Inc is -337.43. This means that Atara Biotherapeutics Inc earned $-337.43 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -194.7%.
What is the trend?
The trend is important because it shows you how Atara Biotherapeutics Inc is performing over time. The most recent quarter might be important if Atara Biotherapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Atara Biotherapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Atara Biotherapeutics Inc with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Atara Biotherapeutics Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Atara Biotherapeutics Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Atara Biotherapeutics Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Atara Biotherapeutics Inc = -74,572
Total revenue MRQ Atara Biotherapeutics Inc = 221
$-74,572 / $221 = -337.43 or -33,743.0%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Atara Biotherapeutics Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
-19.8% Return on Assets means that Atara Biotherapeutics Inc generated $-0.20 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Atara Biotherapeutics Inc:

The MRQ is -19.8%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -15.1%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-19.8%	TTM	-15.1%	-4.7%
TTM	-15.1%	YOY	-18.0%	+2.8%
TTM	-15.1%	5Y	-17.5%	+2.4%
5Y	-17.5%	10Y	-13.5%	-4.0%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-19.8%	-12.4%	-7.4%
TTM	-15.1%	-12.5%	-2.6%
YOY	-18.0%	-10.9%	-7.1%
5Y	-17.5%	-15.3%	-2.2%
10Y	-13.5%	-17.6%	+4.1%

Shows how efficient Atara Biotherapeutics Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Atara Biotherapeutics Inc is using its resources to generate profit. If the return on assets (-19.8%) from Atara Biotherapeutics Inc are higher than the Biotechnology mean (-12.4%) that means Atara Biotherapeutics Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Atara Biotherapeutics Inc is -19.8%. This means the company generated $-0.20 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -12.4%.
What is the trend?
The trend is important because it shows you how Atara Biotherapeutics Inc is performing over time. The most recent quarter might be important if Atara Biotherapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Atara Biotherapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Atara Biotherapeutics Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Atara Biotherapeutics Inc = -74,572
Total assets MRQ (balance sheet) from Atara Biotherapeutics Inc = 376,420
-74,572 / 376,420 = -0.20 or -19.8%

ROA is an important ratio as it will tell you how effectively Atara Biotherapeutics Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Atara Biotherapeutics Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
-58.9% Return on Equity means Atara Biotherapeutics Inc generated $-0.59 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Atara Biotherapeutics Inc:

The MRQ is -58.9%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -34.0%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-58.9%	TTM	-34.0%	-24.9%
TTM	-34.0%	YOY	-26.4%	-7.6%
TTM	-34.0%	5Y	-24.7%	-9.3%
5Y	-24.7%	10Y	-16.9%	-7.8%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-58.9%	-15.2%	-43.7%
TTM	-34.0%	-15.5%	-18.5%
YOY	-26.4%	-13.1%	-13.3%
5Y	-24.7%	-20.4%	-4.3%
10Y	-16.9%	-20.9%	+4.0%

Shows how efficient Atara Biotherapeutics Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Atara Biotherapeutics Inc is -58.9%. This means Atara Biotherapeutics Inc generated $-0.59 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -15.2%.
What is the trend?
The trend is important because it shows you how Atara Biotherapeutics Inc is performing over time. The most recent quarter might be important if Atara Biotherapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Atara Biotherapeutics Inc up to 10 years back (depending if Atara Biotherapeutics Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Atara Biotherapeutics Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Atara Biotherapeutics Inc = -74,572
Shareholders equity (balance sheet) MRQ Atara Biotherapeutics Inc = 126,640
-74,572 / 126,640 = -0.59 or -58.9%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Atara Biotherapeutics Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Atara Biotherapeutics Inc is operating .

Measures how much profit Atara Biotherapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
An Operating Margin of -32,840.3% means the company generated $-328.40 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Atara Biotherapeutics Inc:

The MRQ is -32,840.3%. The company is operating very inefficient. -2
The TTM is -9,001.6%. The company is operating very inefficient. -2

Trends

Current period		Compared to		+/-
MRQ	-32,840.3%	TTM	-9,001.6%	-23,838.6%
TTM	-9,001.6%	YOY	-1,795.8%	-7,205.9%
TTM	-9,001.6%	5Y	-2,159.5%	-6,842.2%
5Y	-2,159.5%	10Y	-1,167.3%	-992.2%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-32,840.3%	-318.9%	-32,521.4%
TTM	-9,001.6%	-267.4%	-8,734.2%
YOY	-1,795.8%	-333.8%	-1,462.0%
5Y	-2,159.5%	-517.0%	-1,642.5%
10Y	-1,167.3%	-624.7%	-542.6%

Measures how efficient Atara Biotherapeutics Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Atara Biotherapeutics Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Atara Biotherapeutics Inc is -32,840.3%. This means that Atara Biotherapeutics Inc earned $-328.40 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -318.9%.
What is the trend?
The trend is important because it shows you how Atara Biotherapeutics Inc is performing over time. The most recent quarter might be important if Atara Biotherapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Atara Biotherapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Atara Biotherapeutics Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Atara Biotherapeutics Inc = -75,539
Total revenue MRQ Atara Biotherapeutics Inc = 221
$-75,539 / $221 = -328.40 or -32,840.3%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Atara Biotherapeutics Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 342.81 means that the operating costs are $342.81 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Atara Biotherapeutics Inc:

The MRQ is 342.805. The company is inefficient in keeping operating costs low. -1
The TTM is 94.367. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	342.805	TTM	94.367	+248.438
TTM	94.367	YOY	18.976	+75.391
TTM	94.367	5Y	22.669	+71.698
5Y	22.669	10Y	12.253	+10.415

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	342.805	3.013	+339.792
TTM	94.367	3.644	+90.723
YOY	18.976	4.537	+14.439
5Y	22.669	6.411	+16.258
10Y	12.253	8.312	+3.941

Measures how efficient Atara Biotherapeutics Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Atara Biotherapeutics Inc is 34,280.5%. This means that Atara Biotherapeutics Inc earned $342.81 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.01.
What is the trend?
The trend is important because it shows you how Atara Biotherapeutics Inc is performing over time. The most recent quarter might be important if Atara Biotherapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Atara Biotherapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Atara Biotherapeutics Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
( +75,760) \ 221 = 342.81

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Atara Biotherapeutics Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 3.74 means the company has $3.74 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Atara Biotherapeutics Inc:

The MRQ is 3.739. The company is very able to pay all its short-term debts. +2
The TTM is 4.009. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	3.739	TTM	4.009	-0.270
TTM	4.009	YOY	4.464	-0.455
TTM	4.009	5Y	8.004	-3.995
5Y	8.004	10Y	17.113	-9.109

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	3.739	4.559	-0.820
TTM	4.009	4.993	-0.984
YOY	4.464	6.149	-1.685
5Y	8.004	6.306	+1.698
10Y	17.113	6.588	+10.525

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Atara Biotherapeutics Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Atara Biotherapeutics Inc is 3.74. This means Atara Biotherapeutics Inc has $3.74 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 4.56.
What is the trend?
The trend is important because it shows you how Atara Biotherapeutics Inc is performing over time. The most recent quarter might be important if Atara Biotherapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Atara Biotherapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Atara Biotherapeutics Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
295,080 \ 78,916) = 3.74

The current ratio measures if Atara Biotherapeutics Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Atara Biotherapeutics Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Atara Biotherapeutics Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Atara Biotherapeutics Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
A Quick Ratio of 5.49 means the company can pay off $5.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Atara Biotherapeutics Inc:

The MRQ is 5.486. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 6.476. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	5.486	TTM	6.476	-0.991
TTM	6.476	YOY	7.171	-0.694
TTM	6.476	5Y	13.400	-6.924
5Y	13.400	10Y	28.385	-14.985

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	5.486	3.881	+1.605
TTM	6.476	4.502	+1.974
YOY	7.171	5.772	+1.399
5Y	13.400	5.816	+7.584
10Y	28.385	6.032	+22.353

Measures if Atara Biotherapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Atara Biotherapeutics Inc can pay off its short term debts. This shows if Atara Biotherapeutics Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Atara Biotherapeutics Inc is 5.49. This means that Atara Biotherapeutics Inc can pay off $5.49 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.88.
What is the trend?
The trend is important because it shows you how Atara Biotherapeutics Inc is performing over time. The most recent quarter might be important if Atara Biotherapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Atara Biotherapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Atara Biotherapeutics Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Atara Biotherapeutics Inc: (242,819 + 149,877 +40,221) / 78,916 = 5.49

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Atara Biotherapeutics Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Atara Biotherapeutics Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Atara Biotherapeutics Inc to Biotechnology industry mean.
A Debt to Asset Ratio of 0.66 means that Atara Biotherapeutics Inc assets are financed with 66.4% credit (debt) and the remaining percentage (100% - 66.4%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Atara Biotherapeutics Inc:

The MRQ is 0.664. The company is able to pay all its debts by selling its assets. +1
The TTM is 0.500. The company is able to pay all its debts by selling its assets. +1

Trends

Current period		Compared to		+/-
MRQ	0.664	TTM	0.500	+0.163
TTM	0.500	YOY	0.309	+0.192
TTM	0.500	5Y	0.239	+0.261
5Y	0.239	10Y	0.255	-0.016

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.664	0.311	+0.353
TTM	0.500	0.298	+0.202
YOY	0.309	0.269	+0.040
5Y	0.239	0.377	-0.138
10Y	0.255	0.409	-0.154

Measures how much % of Atara Biotherapeutics Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Atara Biotherapeutics Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Atara Biotherapeutics Inc to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Atara Biotherapeutics Inc is 0.66. This means means that Atara Biotherapeutics Inc is financed with 66.4% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 455.9%.
What is the trend?
The trend is important because it shows you how Atara Biotherapeutics Inc is performing over time. The most recent quarter might be important if Atara Biotherapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Atara Biotherapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Atara Biotherapeutics Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Atara Biotherapeutics Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
249,780 \ 376,420 = 66.4% or 0.66.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Atara Biotherapeutics Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
A Debt to Equity ratio of 197.2% means that company has $1.97 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Atara Biotherapeutics Inc:

The MRQ is 1.972. The company is just able to pay all its debts with equity.
The TTM is 1.101. The company is able to pay all its debts with equity. +1

Trends

Current period		Compared to		+/-
MRQ	1.972	TTM	1.101	+0.871
TTM	1.101	YOY	0.457	+0.644
TTM	1.101	5Y	0.402	+0.700
5Y	0.402	10Y	0.240	+0.161

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	1.972	0.363	+1.609
TTM	1.101	0.362	+0.739
YOY	0.457	0.277	+0.180
5Y	0.402	0.424	-0.022
10Y	0.240	0.463	-0.223

Measures if Atara Biotherapeutics Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Atara Biotherapeutics Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Atara Biotherapeutics Inc is 1.97. This means that Atara Biotherapeutics Inc can pay off $1.97 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.36.
What is the trend?
The trend is important because it shows you how Atara Biotherapeutics Inc is performing over time. The most recent quarter might be important if Atara Biotherapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Atara Biotherapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Atara Biotherapeutics Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
249,780 \ 126,640 = 1.97 or 197.2%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Atara Biotherapeutics Inc

2. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Atara Biotherapeutics Inc generates.

Above 15 is considered overpriced but always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
A PE ratio of -4.54 means the investor is paying $-4.54 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Atara Biotherapeutics Inc:

The EOD is -2.601. Company is losing money. -2
The MRQ is -4.538. Company is losing money. -2
The TTM is 5.802. Very good. +2

Trends

Current period		Compared to		+/-
EOD	-2.601	MRQ	-4.538	+1.937
MRQ	-4.538	TTM	5.802	-10.341
TTM	5.802	YOY	-18.130	+23.933
TTM	5.802	5Y	-25.668	+31.470
5Y	-25.668	10Y	-64.109	+38.441

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-2.601	-6.504	+3.903
MRQ	-4.538	-7.165	+2.627
TTM	5.802	-8.417	+14.219
YOY	-18.130	-19.810	+1.680
5Y	-25.668	-18.328	-7.340
10Y	-64.109	-18.049	-46.060

Measures how much money you pay for each share for every $1 in earnings Atara Biotherapeutics Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Atara Biotherapeutics Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Atara Biotherapeutics Inc is -4.54. This means the investor is paying $-4.54 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -7.17.
What is the trend?
The trend is important because it shows you how Atara Biotherapeutics Inc is performing over time. The most recent quarter might be important if Atara Biotherapeutics Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Atara Biotherapeutics Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Atara Biotherapeutics Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
-74,572 \ 103,178 = EPS
PE ratio MRQ = -4.54

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Atara Biotherapeutics Inc.

Lower is better.
A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Atara Biotherapeutics Inc:

The MRQ is -4.053. Very Bad. -2
The TTM is 1.666. Seems overpriced? -1

Trends

Current period		Compared to		+/-
MRQ	-4.053	TTM	1.666	-5.719
TTM	1.666	YOY	-18.789	+20.455
TTM	1.666	5Y	-30.373	+32.039
5Y	-30.373	10Y	-98.630	+68.257

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-4.053	-4.287	+0.234
TTM	1.666	-6.137	+7.803
YOY	-18.789	-13.849	-4.940
5Y	-30.373	-12.525	-17.848
10Y	-98.630	-11.713	-86.917

PEG Ratio	Meaning
0.5	You can buy the stock cheap based on future growth
1	You pay a fair price based on future growth
2	The stock is overpriced based on future growth

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Atara Biotherapeutics Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 2.67 means the investor is paying $2.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Atara Biotherapeutics Inc:

The EOD is 1.532. Good. +1
The MRQ is 2.672. Good. +1
The TTM is 2.999. Good. +1

Trends

Current period		Compared to		+/-
EOD	1.532	MRQ	2.672	-1.141
MRQ	2.672	TTM	2.999	-0.326
TTM	2.999	YOY	4.769	-1.770
TTM	2.999	5Y	5.678	-2.679
5Y	5.678	10Y	7.378	-1.700

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	1.532	1.991	-0.459
MRQ	2.672	2.024	+0.648
TTM	2.999	2.335	+0.664
YOY	4.769	3.965	+0.804
5Y	5.678	3.738	+1.940
10Y	7.378	4.004	+3.374

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Atara Biotherapeutics Inc.

3.1. Institutions holding Atara Biotherapeutics Inc

Institutions are holding 103.982% of the shares of Atara Biotherapeutics Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2022-12-31	BlackRock Inc	9.5219	0.0009	9152149	240158	2.6948
2022-12-31	Wasatch Advisors Inc.	8.73	0.1853	8391014	254651	3.1298
2022-12-31	Baupost Group LLC	8.4518	0.4346	8123616	0	0
2022-12-31	State Street Corporation	7.9588	0.0015	7649740	-447613	-5.5279
2022-12-31	JPMorgan Chase & Co	7.8024	0.0032	7499435	-783953	-9.4642
2022-12-31	Vanguard Group Inc	7.5023	0.0006	7211048	604539	9.1507
2022-12-31	Maverick Capital Ltd	6.5451	0.4886	6291013	-1564811	-19.9191
2022-12-31	Goldman Sachs Group Inc	6.4958	0.0046	6243613	1484933	31.2047
2022-12-31	Redmile Group, LLC	6.4949	0.8376	6242756	0	0
2022-12-31	D. E. Shaw & Co LP	3.6747	0.0128	3532000	812100	29.8577
2022-12-31	Morgan Stanley - Brokerage Accounts	2.7984	0.001	2689744	-259172	-8.7887
2022-09-30	KPCB XV Associates LLC	1.9525	19.7946	1876650	0	0
2022-12-31	Geode Capital Management, LLC	1.9181	0.0009	1843618	72294	4.0814
2022-12-31	Citadel Advisors Llc	1.4542	0.0011	1397765	1366179	4325.2675
2022-12-31	Ameriprise Financial Inc	1.3873	0.0015	1333420	460844	52.8142
2022-12-31	Nuveen Asset Management, LLC	1.3263	0.0016	1274847	752345	143.9889
2022-12-31	Citigroup Inc	1.0668	0.0027	1025418	-264213	-20.4875
2022-12-31	Antipodean Advisors LLC	1.0404	10.9516	1000000	0	0
2022-12-31	Jacobs Levy Equity Management, Inc.	1.0022	0.0214	963272	607947	171.096
2022-12-31	Dimensional Fund Advisors, Inc.	0.924	0.0009	888165	271197	43.9564
Total		88.0479	32.747	84629283	+3607425	+4.3%

3.2. Funds holding Atara Biotherapeutics Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-03-31	SPDR® S&P Biotech ETF	5.4144	0.2344	5204123	-60567	-1.1504
2022-12-31	Vanguard Instl Ttl Stck Mkt Idx Tr	2.8197	0.0008	2710236	367196	15.6718
2023-03-31	Vanguard Total Stock Mkt Idx Inv	2.8197	0.0006	2710236	0	0
2023-02-28	JPMorgan Small Cap Growth A	2.5262	0.2469	2428081	0	0
2022-12-31	Wasatch Small Cap Growth Investor	2.4675	0.3933	2371687	-70450	-2.8848
2023-03-31	JPM Global Healthcare C (acc) USD	2.3297	0.1352	2239196	0	0
2023-03-31	iShares Russell 2000 ETF	2.0958	0.0118	2014393	-22806	-1.1195
2022-12-31	Wasatch Ultra Growth	1.958	0.4708	1881974	-20204	-1.0622
2022-12-31	Wasatch Small Cap Value	1.4288	0.3366	1373334	0	0
2023-03-31	Vanguard Extended Market Index Investor	1.4128	0.0046	1357911	27092	2.0357
2023-01-31	Vanguard Explorer Inv	1.1578	0.0277	1112882	0	0
2023-03-31	iShares Russell 2000 Value ETF	0.9336	0.0227	897346	3228	0.361
2023-03-31	State St Russell Sm/Mid Cp® Indx NL Cl C	0.8877	0.0078	853277	0	0
2023-03-31	JPM Thematics Genetic Thrps C2 Acc USD	0.84	0.2439	807374	0	0
2023-01-31	Fidelity® Small Cap Index	0.804	0.0188	772782	16521	2.1846
2023-02-28	CREF Stock R1	0.754	0.0027	724681	89040	14.0079
2023-03-31	Columbia Small Cap Value I	0.7487	0.155	719670	23000	3.3014
2023-03-31	Columbia Small Cap Value I A	0.7487	0.1551	719670	6500	0.9114
2023-03-31	iShares Biotechnology ETF	0.7422	0.0258	713350	-574	-0.0804
2023-03-31	Xtrackers S&P Global Infras Swap ETF 1C	0.6761	0.6324	649808	649808	0
Total		33.5654	3.1269	32262011	+1007784	+3.1%

3.3. Insider Transactions

Insiders are holding 1.626% of the shares of Atara Biotherapeutics Inc.

Date	Owner	Type	Amount	Price	Post Transaction Amount
2023-03-02	Jakob Dupont	SELL	5074	3.63	290794
2023-03-02	Pascal Touchon	SELL	15679	3.63	750728
2023-03-02	Utpal Koppikar	SELL	6871	3.63	181978
2023-03-02	Amar Murugan	SELL	4221	3.63	279334
2023-02-07	Utpal Koppikar	SELL	2485	5.46	188849
2022-11-16	Amar Murugan	SELL	3612	4.49	127586
2022-11-16	Jakob Dupont	SELL	4342	4.49	154540
2022-11-16	Pascal Touchon	SELL	15591	4.49	441696
2022-11-16	Utpal Koppikar	SELL	6255	4.49	191334
2022-08-16	Amar Murugan	SELL	3430	5.03	131198
2022-08-16	Utpal Koppikar	SELL	5940	5.04	197589
2022-08-16	Pascal Touchon	SELL	14806	5.04	457287
2022-08-16	Jakob Dupont	SELL	4124	5.03	158882
2022-06-27	Pascal Touchon	SELL	14220	7.2	472093
2022-05-17	Amar Murugan	SELL	3223	5.32	133735
2022-05-17	Jakob Dupont	SELL	3873	5.32	163006
2022-05-17	Pascal Touchon	SELL	13913	5.32	486313
2022-05-17	Utpal Koppikar	SELL	5582	5.32	207592

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Atara Biotherapeutics Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	-0.599	-0.411	-31%	-0.479	-20%	-0.031	-95%	0.033	-1907%
Book Value Growth	-	-	0.677	0.838	-19%	0.883	-23%	1.033	-35%	1.288	-47%
Book Value Per Share	-	-	1.227	1.952	-37%	3.410	-64%	3.251	-62%	2.605	-53%
Book Value Per Share Growth	-	-	0.672	0.826	-19%	0.881	-24%	1.031	-35%	1.286	-48%
Current Ratio	-	-	3.739	4.009	-7%	4.464	-16%	8.004	-53%	17.113	-78%
Debt To Asset Ratio	-	-	0.664	0.500	+33%	0.309	+115%	0.239	+178%	0.255	+160%
Debt To Equity Ratio	-	-	1.972	1.101	+79%	0.457	+331%	0.402	+391%	0.240	+721%
Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Eps	-	-	-0.723	-0.559	-23%	-0.878	+21%	-0.716	-1%	-0.472	-35%
Eps Growth	-	-	1.120	-0.029	+103%	0.966	+16%	0.739	+52%	0.690	+62%
Free Cash Flow Per Share	-	-	-0.552	-0.674	+22%	-0.597	+8%	-0.587	+6%	-0.381	-31%
Free Cash Flow Per Share Growth	-	-	1.133	0.776	+46%	-2.222	+296%	0.324	+250%	0.420	+170%
Free Cash Flow To Equity Per Share	-	-	-0.239	-0.544	+128%	-0.329	+38%	-0.003	-99%	0.043	-650%
Free Cash Flow To Equity Per Share Growth	-	-	1.626	-0.187	+111%	1.340	+21%	1.515	+7%	2.015	-19%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	1.000	0%	1.000	0%
Intrinsic Value_10Y_max	-	-	13.619	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-24.088	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	-1.801	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-2.664	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	-2.998	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-7.836	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	-1.287	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-12.781	-	-	-	-	-	-	-	-
Net Profit Margin	-	-	-337.430	-91.990	-73%	-17.960	-95%	-21.990	-93%	-11.886	-96%
Operating Margin	-	-	-328.403	-90.016	-73%	-17.958	-95%	-21.595	-93%	-11.673	-96%
Operating Ratio	-	-	342.805	94.367	+263%	18.976	+1707%	22.669	+1412%	12.253	+2698%
Pb Ratio	1.532	-74%	2.672	2.999	-11%	4.769	-44%	5.678	-53%	7.378	-64%
Pe Ratio	-2.601	+43%	-4.538	5.802	-178%	-18.130	+299%	-25.668	+466%	-64.109	+1313%
Peg Ratio	-	-	-4.053	1.666	-343%	-18.789	+364%	-30.373	+649%	-98.630	+2333%
Price Per Share	1.880	-74%	3.280	6.035	-46%	15.893	-79%	19.284	-83%	19.214	-83%
Price To Total Gains Ratio	-3.136	+43%	-5.471	0.153	-3679%	-42.875	+684%	-10.569	+93%	-43.536	+696%
Profit Growth	-	-	1.113	-0.043	+104%	0.963	+16%	0.735	+51%	0.755	+47%
Quick Ratio	-	-	5.486	6.476	-15%	7.171	-23%	13.400	-59%	28.385	-81%
Return On Assets	-	-	-0.198	-0.151	-24%	-0.180	-9%	-0.175	-12%	-0.135	-32%
Return On Equity	-	-	-0.589	-0.340	-42%	-0.264	-55%	-0.247	-58%	-0.169	-71%
Revenue Growth	-	-	0.050	2.039	-98%	1.294	-96%	1.720	-97%	1.720	-97%
Total Gains Per Share	-	-	-0.599	-0.411	-31%	-0.479	-20%	-0.031	-95%	0.033	-1907%
Total Gains Per Share Growth	-	-	1.145	0.346	+231%	0.625	+83%	1.478	-23%	2.082	-45%
Usd Book Value	-	-	126640000.000	198887000.000	-36%	330082500.000	-62%	316256450.000	-60%	252867459.459	-50%
Usd Book Value Change Per Share	-	-	-0.599	-0.411	-31%	-0.479	-20%	-0.031	-95%	0.033	-1907%
Usd Book Value Per Share	-	-	1.227	1.952	-37%	3.410	-64%	3.251	-62%	2.605	-53%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Eps	-	-	-0.723	-0.559	-23%	-0.878	+21%	-0.716	-1%	-0.472	-35%
Usd Free Cash Flow	-	-	-56917000.000	-68655750.000	+21%	-57775500.000	+2%	-57402650.000	+1%	-37174081.081	-35%
Usd Free Cash Flow Per Share	-	-	-0.552	-0.674	+22%	-0.597	+8%	-0.587	+6%	-0.381	-31%
Usd Free Cash Flow To Equity Per Share	-	-	-0.239	-0.544	+128%	-0.329	+38%	-0.003	-99%	0.043	-650%
Usd Price Per Share	1.880	-74%	3.280	6.035	-46%	15.893	-79%	19.284	-83%	19.214	-83%
Usd Profit	-	-	-74572000.000	-57046750.000	-24%	-85035250.000	+14%	-69831150.000	-6%	-45512054.054	-39%
Usd Revenue	-	-	221000.000	15893250.000	-99%	5085000.000	-96%	4195650.000	-95%	2267918.919	-90%
Usd Total Gains Per Share	-	-	-0.599	-0.411	-31%	-0.479	-20%	-0.031	-95%	0.033	-1907%
	EOD	+3 -2	MRQ	TTM	+14 -25	YOY	+16 -23	5Y	+10 -29	10Y	+6 -33

4.2. Fundamental Score

Let's check the fundamental score of Atara Biotherapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-2.601
Price to Book Ratio (EOD)	Between	0-1	1.532
Net Profit Margin (MRQ)	Greater than	0	-337.430
Operating Margin (MRQ)	Greater than	0	-328.403
Quick Ratio (MRQ)	Greater than	1	5.486
Current Ratio (MRQ)	Greater than	1	3.739
Debt to Asset Ratio (MRQ)	Less than	1	0.664
Debt to Equity Ratio (MRQ)	Less than	1	1.972
Return on Equity (MRQ)	Greater than	0.15	-0.589
Return on Assets (MRQ)	Greater than	0.05	-0.198
Total			3/10 (30.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Atara Biotherapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Open	Greater than	Close	1.640
Total			0/1 (0.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	376,420
Total Liabilities	249,780
Total Stockholder Equity	126,640

	As reported
Total Liabilities	249,780
Total Stockholder Equity	+ 126,640
Total Assets	= 376,420

Assets

Total Assets	376,420
Total Current Assets	295,080
Long-term Assets	295,080

Total Current Assets

Total Current Assets (as reported)	295,080
Cash And Cash Equivalents	92,942
Short-term Investments	149,877
Net Receivables	40,221
Inventory	1,586
Other Current Assets	10,308
Total Current Assets (calculated)	294,934
+/-	146

Long-term Assets

Long-term Assets (as reported)	81,340
Property Plant Equipment	74,322
Long-term Assets Other	7,018
Long-term Assets (calculated)	81,340
+/-	0

Liabilities & Shareholders' Equity

Total Current Liabilities	78,916
Long-term Liabilities	170,864
Total Stockholder Equity	126,640

Total Current Liabilities

Total Current Liabilities (as reported)	78,916
Short-term Debt	13,640
Accounts payable	6,871
Other Current Liabilities	50,405
Total Current Liabilities (calculated)	70,916
+/-	8,000

Long-term Liabilities

Long-term Liabilities (as reported)	170,864
Capital Lease Obligations Min Short Term Debt	58,064
Long-term Liabilities Other	170,864
Long-term Liabilities (calculated)	228,928
+/-	58,064

Total Stockholder Equity

Total Stockholder Equity (as reported)	126,640
Common Stock	10
Retained Earnings	-1,693,024
Accumulated Other Comprehensive Income	-2,067
Capital Surplus	1,821,721
Total Stockholder Equity (calculated)	126,640
+/-	0

Other

Capital Stock	10
Cash and Short Term Investments	242,819
Common Stock Shares Outstanding	103,178
Common Stock Total Equity	10
Current Deferred Revenue	8,000
Liabilities and Stockholders Equity	376,420
Net Debt	-34,878
Net Invested Capital	126,640
Net Tangible Assets	126,640
Net Working Capital	216,164
Short Long Term Debt Total	58,064

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

> Total Assets

4,290
0
0
0
51,828
62,866
58,503
54,120
106,122
169,817
161,102
340,379
324,975
312,978
300,814
284,417
263,914
241,738
244,155
229,693
217,779
473,108
492,707
442,940
391,839
324,726
274,144
364,785
342,942
299,547
428,111
405,532
588,120
529,637
456,791
449,923
468,127
397,280
436,121
368,316
376,420

376,420

368,316

436,121

397,280

468,127

449,923

456,791

529,637

588,120

405,532

428,111

299,547

342,942

364,785

274,144

324,726

391,839

442,940

492,707

473,108

217,779

229,693

244,155

241,738

263,914

284,417

300,814

312,978

324,975

340,379

161,102

169,817

106,122

54,120

58,503

62,866

51,828

4,290

> Total Current Assets

0
0
0
0
51,808
62,291
57,085
52,022
106,026
169,691
160,634
340,235
324,597
311,741
298,883
282,230
260,553
235,318
222,492
206,217
172,190
413,614
425,070
372,976
321,489
250,830
201,139
293,418
272,992
229,217
358,987
339,432
523,273
464,307
392,325
369,497
384,621
314,389
346,984
283,046
295,080

295,080

283,046

346,984

314,389

384,621

369,497

392,325

464,307

523,273

339,432

358,987

229,217

272,992

293,418

201,139

250,830

321,489

372,976

425,070

413,614

172,190

206,217

222,492

235,318

260,553

282,230

298,883

311,741

324,597

340,235

160,634

169,691

106,026

52,022

57,085

62,291

51,808

Cash And Cash Equivalents

4,207
0
0
0
51,615
39,754
31,779
25,703
21,897
71,329
26,190
54,466
23,746
22,056
26,356
46,013
47,968
62,430
64,237
60,493
79,223
90,495
103,203
66,028
60,698
56,168
59,159
94,431
74,317
70,203
74,511
62,620
200,404
151,097
123,856
113,209
106,084
101,669
70,688
65,114
92,942

92,942

65,114

70,688

101,669

106,084

113,209

123,856

151,097

200,404

62,620

74,511

70,203

74,317

94,431

59,159

56,168

60,698

66,028

103,203

90,495

79,223

60,493

64,237

62,430

47,968

46,013

26,356

22,056

23,746

54,466

26,190

71,329

21,897

25,703

31,779

39,754

51,615

4,207

Short-term Investments

0
0
0
0
0
22,277
24,719
25,996
82,219
95,367
128,841
279,799
296,736
284,347
268,201
232,134
207,714
168,216
152,659
139,728
86,873
316,826
313,812
298,515
248,933
181,377
130,976
188,491
184,792
144,428
273,201
264,565
300,255
284,064
249,524
244,036
264,984
200,142
260,623
200,290
149,877

149,877

200,290

260,623

200,142

264,984

244,036

249,524

284,064

300,255

264,565

273,201

144,428

184,792

188,491

130,976

181,377

248,933

298,515

313,812

316,826

86,873

139,728

152,659

168,216

207,714

232,134

268,201

284,347

296,736

279,799

128,841

95,367

82,219

25,996

24,719

22,277

Net Receivables

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
800
800
1,250
9,610
700
400
986
668
637
249
40,221

40,221

249

637

668

986

400

700

9,610

1,250

800

Inventory

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,586

1,586

> Long-term Assets

0
0
0
0
20
575
1,418
2,098
96
126
468
144
378
1,237
1,931
2,187
3,361
6,420
21,663
23,476
45,589
59,494
67,637
69,964
70,350
73,896
73,005
71,367
69,950
70,330
69,124
66,100
64,847
65,330
64,466
80,426
83,506
82,891
89,137
85,270
81,340

81,340

85,270

89,137

82,891

83,506

80,426

64,466

65,330

64,847

66,100

69,124

70,330

69,950

71,367

73,005

73,896

70,350

69,964

67,637

59,494

45,589

23,476

21,663

6,420

3,361

2,187

1,931

1,237

378

144

468

126

2,098

1,418

575

Property Plant Equipment

9
0
0
0
8
8
11
14
48
47
42
46
270
1,148
1,830
2,085
3,259
4,400
20,287
22,176
44,129
58,194
66,075
68,279
68,576
72,160
71,486
69,901
68,183
68,133
66,908
64,023
62,820
63,401
62,577
78,556
79,939
28,042
81,910
78,104
74,322

74,322

78,104

81,910

28,042

79,939

78,556

62,577

63,401

62,820

64,023

66,908

68,133

68,183

69,901

71,486

72,160

68,576

68,279

66,075

58,194

44,129

22,176

20,287

4,400

3,259

2,085

1,830

1,148

270

Long-term Assets Other

0
0
0
0
12
567
1,407
2,084
48
79
426
98
108
89
101
102
102
2,020
1,376
1,300
1,460
1,300
1,562
1,685
1,774
1,736
1,519
1,466
1,767
2,197
2,216
2,077
2,027
1,929
1,889
1,870
3,567
54,849
7,227
7,166
7,018

7,018

7,166

7,227

54,849

3,567

1,870

1,889

1,929

2,027

2,077

2,216

2,197

1,767

1,466

1,519

1,736

1,774

1,685

1,562

1,300

1,460

1,300

1,376

2,020

102

101

108

426

2,084

1,407

567

> Total Liabilities

1,306
0
0
0
62,845
77,570
2,280
77,149
2,940
3,723
11,847
6,631
9,875
9,144
10,569
14,215
10,178
8,604
23,011
23,737
39,915
33,924
40,208
39,886
52,982
40,792
41,865
46,343
52,161
46,725
46,986
51,597
125,781
130,600
125,253
139,782
188,513
172,964
178,642
181,203
249,780

249,780

181,203

178,642

172,964

188,513

139,782

125,253

130,600

125,781

51,597

46,986

46,725

52,161

46,343

41,865

40,792

52,982

39,886

40,208

33,924

39,915

23,737

23,011

8,604

10,178

14,215

10,569

9,144

9,875

6,631

11,847

3,723

2,940

77,149

2,280

77,570

62,845

1,306

> Total Current Liabilities

1,302
0
0
0
1,524
2,788
2,101
2,412
2,724
3,514
11,644
6,450
9,709
8,860
10,006
13,688
9,675
7,805
11,481
16,516
27,646
21,049
27,234
27,000
39,979
25,175
25,803
30,706
36,743
31,520
31,684
36,055
82,901
84,194
88,830
86,150
105,786
101,562
65,688
72,244
78,916

78,916

72,244

65,688

101,562

105,786

86,150

88,830

84,194

82,901

36,055

31,684

31,520

36,743

30,706

25,803

25,175

39,979

27,000

27,234

21,049

27,646

16,516

11,481

7,805

9,675

13,688

10,006

8,860

9,709

6,450

11,644

3,514

2,724

2,412

2,101

2,788

1,524

1,302

Short-term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
10,300
10,300
0
0
643
0
0
1,581
0
0
0
1,985
0
0
0
2,753
0
0
0
13,640

13,640

2,753

1,985

1,581

643

10,300

500

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
10,300
10,300
0
0
643
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

643

10,300

500

Accounts payable

121
0
0
0
606
1,402
577
569
440
794
1,703
1,853
1,445
1,896
3,235
4,463
2,778
2,204
5,243
5,539
14,711
6,098
6,545
6,193
3,719
6,168
6,420
5,155
7,963
8,079
5,106
5,190
7,118
17,355
12,301
16,543
17,368
11,945
12,799
11,296
6,871

6,871

11,296

12,799

11,945

17,368

16,543

12,301

17,355

7,118

5,190

5,106

8,079

7,963

5,155

6,420

6,168

3,719

6,193

6,545

6,098

14,711

5,539

5,243

2,204

2,778

4,463

3,235

1,896

1,445

1,853

1,703

794

440

569

577

1,402

606

121

Other Current Liabilities

1,174
0
0
0
918
1,386
1,524
1,843
2,284
2,720
9,941
4,597
8,264
6,964
6,771
9,225
6,897
5,601
6,238
10,977
12,935
14,951
20,689
20,807
36,260
19,007
19,383
25,551
27,199
23,441
26,578
30,865
40,343
31,342
35,561
38,381
44,905
38,674
51,218
58,286
50,405

50,405

58,286

51,218

38,674

44,905

38,381

35,561

31,342

40,343

30,865

26,578

23,441

27,199

25,551

19,383

19,007

36,260

20,807

20,689

14,951

12,935

10,977

6,238

5,601

6,897

9,225

6,771

6,964

8,264

4,597

9,941

2,720

2,284

1,843

1,524

1,386

918

1,174

> Long-term Liabilities

0
0
0
0
61,321
74,782
179
74,737
216
209
203
181
166
284
563
527
503
799
11,530
7,221
12,269
12,875
12,974
12,886
13,003
15,617
16,062
15,637
15,418
15,205
15,302
15,542
42,880
46,406
36,423
53,632
82,727
71,402
112,954
108,959
170,864

170,864

108,959

112,954

71,402

82,727

53,632

36,423

46,406

42,880

15,542

15,302

15,205

15,418

15,637

16,062

15,617

13,003

12,886

12,974

12,875

12,269

7,221

11,530

799

503

527

563

284

166

181

203

209

216

74,737

179

74,782

61,321

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196
141
85
244
0
0
0
0
0
0
0
0
0
0
0
0

244

141

196

Capital Lease Obligations Min Short Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-500
-10,300
-10,300
0
0
13,794
14,919
14,532
14,136
13,809
13,420
13,129
13,041
12,569
12,182
24,574
22,765
17,453
63,999
61,072
58,064

58,064

61,072

63,999

17,453

22,765

24,574

12,182

12,569

13,041

13,129

13,420

13,809

14,136

14,532

14,919

13,794

-10,300

-500

Warrants

0
0
0
0
0
0
0
149,144
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

149,144

Long-term Liabilities Other

0
0
0
0
0
0
0
165
216
209
203
181
0
0
0
0
0
0
0
0
0
0
0
0
0
15,617
16,062
15,637
15,418
15,205
15,302
15,542
42,880
46,406
1,771
53,632
1,501
71,402
5,626
108,959
170,864

170,864

108,959

5,626

71,402

1,501

53,632

1,771

46,406

42,880

15,542

15,302

15,205

15,418

15,637

16,062

15,617

181

203

209

216

165

> Total Stockholder Equity

2,984
0
0
0
-11,017
-14,704
56,223
-23,029
103,182
166,094
149,255
333,748
315,100
303,834
290,245
270,202
253,736
233,134
221,144
205,956
177,864
439,184
452,499
403,054
338,857
283,934
232,279
318,442
290,781
252,822
381,125
353,935
462,339
399,037
331,538
310,141
279,614
224,316
257,479
187,113
126,640

126,640

187,113

257,479

224,316

279,614

310,141

331,538

399,037

462,339

353,935

381,125

252,822

290,781

318,442

232,279

283,934

338,857

403,054

452,499

439,184

177,864

205,956

221,144

233,134

253,736

270,202

290,245

303,834

315,100

333,748

149,255

166,094

103,182

-23,029

56,223

-14,704

-11,017

2,984

Common Stock

1
0
0
0
1
0
1
0
2
2
2
3
3
3
3
3
3
3
3
3
3
4
5
5
5
5
5
5
6
6
7
8
8
8
8
9
9
9
9
9
10

Retained Earnings Total Equity

-1,693,024

-1,618,452

-1,534,361

-1,552,827

-1,464,722

-1,371,373

-1,286,709

-1,202,916

-1,124,581

-1,043,274

-968,926

-891,470

-817,961

-739,465

-667,570

-593,242

-527,349

-447,337

-388,976

-338,093

-296,650

-261,337

-230,241

-202,813

-177,159

-158,924

-133,551

-114,671

-98,110

-76,862

-64,994

-50,049

-40,889

-30,362

Accumulated Other Comprehensive Income

0
0
0
0
-3,823
-11
0
-11
-100
-18
-66
51
-518
51
193
35
-183
-152
-114
-88
-151
-524
-505
-449
-340
38
173
233
220
204
810
527
296
161
62
24
-368
-1,892
-2,618
-2,959
-2,067

-2,067

-2,959

-2,618

-1,892

-368

161

296

527

810

204

220

233

173

-340

-449

-505

-524

-151

-88

-114

-152

-183

193

-518

-66

-18

-100

-11

-3,823

Capital Surplus

0
0
0
0
0
0
0
7,344
144,169
216,159
214,313
410,556
413,725
418,451
423,600
429,088
431,075
436,096
451,496
467,378
474,662
777,797
841,975
850,835
866,541
877,133
899,671
1,057,669
1,108,516
1,144,082
1,349,234
1,396,674
1,586,616
1,601,784
1,618,177
1,681,481
1,744,695
1,779,026
1,794,449
1,808,515
1,821,721

1,821,721

1,808,515

1,794,449

1,779,026

1,744,695

1,681,481

1,618,177

1,601,784

1,586,616

1,396,674

1,349,234

1,144,082

1,108,516

1,057,669

899,671

877,133

866,541

850,835

841,975

777,797

474,662

467,378

451,496

436,096

431,075

429,088

423,600

418,451

413,725

410,556

214,313

216,159

144,169

7,344

Treasury Stock

Other Stockholders Equity

0
0
0
0
1,865
5,239
84,477
7,344
144,169
216,159
214,313
410,556
413,725
418,451
423,600
429,088
431,075
436,096
451,496
467,378
474,662
777,797
841,975
850,835
866,541
877,133
899,671
1,057,669
1,108,516
1,144,082
1,349,234
1,396,674
1,586,616
1,601,784
1,618,177
1,681,481
1,744,695
1,779,026
1,794,449
1,808,515
1,821,721

1,821,721

1,808,515

1,794,449

1,779,026

1,744,695

1,681,481

1,618,177

1,601,784

1,586,616

1,396,674

1,349,234

1,144,082

1,108,516

1,057,669

899,671

877,133

866,541

850,835

841,975

777,797

474,662

467,378

451,496

436,096

431,075

429,088

423,600

418,451

413,725

410,556

214,313

216,159

144,169

7,344

84,477

5,239

1,865

Balance Sheet

Currency in USD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Accounts Payable	6,871	17,368	7,118	7,963	3,719	14,711	2,778	1,445	440	606	121
Accumulated Other Comprehensive Income	-2,067	-368	296	220	-340	-151	-183	-518	-100	-3,823	-
Additional Paid In Capital	-	-	-	-	-	0	0	0	0	-	-
Capital Lease Obligations	71,704	25,518	15,026	15,717	-	-	-	-	-	-	-
Capital Stock	10	9	8	6	5	-	-	-	-	-	-
Capital Surpluse	1,821,721	1,744,695	1,586,616	1,108,516	866,541	474,662	431,075	413,725	144,169	-	-
Cash	92,942	106,084	200,404	74,317	60,698	79,223	47,968	23,746	21,897	51,615	4,207
Cash And Short Term Investments	242,819	371,068	500,659	259,109	309,631	166,096	255,682	320,482	104,116	51,615	4,207
Common Stock	10	9	8	6	5	3	3	3	2	1	1
Common Stock Shares Outstanding	101,990	93,670	73,973	51,308	43,811	29,863	28,732	25,583	4,986	6,871	1,000
Common Stock Total Equity	10	9	8	6	5	3	3	3	2	1	1
Current Deferred Revenue	8,000	40,760	33,455	-	-	-	-	-	-	-	-
Deferred Long Term Liab	-	-	-	-	-	0	0	0	0	-	-
Good Will	-	-	-	-	-	0	0	0	0	-	-
Intangible Assets	-	-	-	-	-	0	0	0	0	-	-
Inventory	1,586	-	-	-	-	0	0	0	0	-	-
Liabilities And Stockholders Equity	376,420	468,127	588,120	342,942	391,839	217,779	263,914	324,975	106,122	51,828	4,290
Long Term Debt	-	-	-	-	-	10,513	0	0	0	-	-
Long Term Debt Total	-	-	-	244	-	-	-	-	-	-	-
Net Debt	-34,878	-80,566	-187,363	-60,181	-60,698	-79,223	-47,968	-23,746	-21,897	-51,615	-4,207
Net Invested Capital	126,640	279,614	462,339	290,781	338,857	177,864	-	-	-	-	-
Net Receivables	40,221	986	1,250	-	-	-	-	-	-	-	-
Net Tangible Assets	126,640	279,614	462,339	290,781	338,857	177,864	253,736	315,100	103,182	-	-
Net Working Capital	216,164	278,835	440,372	236,249	281,510	144,544	-	-	-	-	-
Non Current Assets Total	81,340	83,506	64,847	69,950	70,350	45,589	3,361	378	96	20	48
Non Current Liabilities Other	170,864	1,501	42,880	15,418	13,003	12,269	503	-	216	-	-
Non Current Liabilities Total	170,864	82,727	42,880	15,418	13,003	12,269	503	166	216	61,321	6,715
Non Currrent Assets Other	7,018	3,567	2,027	1,767	1,774	1,460	102	108	48	12	39
Noncontrolling Interest In Consolidated Entity	-	-	-	-	-	0	0	0	0	-	-
Other Assets	-	3,567	14,330	1,767	1,774	1,460	102	108	48	12	39
Other Current Assets	10,308	12,567	21,364	13,883	11,858	6,094	4,871	4,115	1,910	193	35
Other Current Liab	50,405	44,905	40,343	27,199	36,260	12,935	6,897	8,264	2,284	918	1,181
Other Liab	-	57,209	29,690	1,038	13,003	12,269	503	166	216	230	4
Other Stockholder Equity	1,821,721	1,744,695	1,586,616	1,108,516	866,541	474,662	431,075	413,725	144,169	1,865	382
Preferred Stock Total Equity	-	-	-	-	-	0	0	0	0	61,091	6,711
Property Plant And Equipment Gross	-	-	62,820	68,183	68,576	44,129	3,259	270	48	8	9
Property Plant And Equipment Net	74,322	79,939	62,820	68,183	68,576	44,129	3,259	270	48	8	9
Property Plant Equipment	6,300	79,939	50,517	54,176	68,576	44,129	3,259	270	48	8	9
Retained Earnings	-1,693,024	-1,464,722	-1,124,581	-817,961	-527,349	-296,650	-177,159	-98,110	-40,889	-12,883	-4,110
Retained Earnings Total Equity	-1,693,024	-1,464,722	-1,124,581	-817,961	-527,349	-296,650	-177,159	-98,110	-40,889	-	-
Short Long Term Debt	-	-	-	-	-	500	-	-	-	-	-
Short Long Term Debt Total	58,064	25,518	13,041	14,136	-	-	-	-	-	-	-
Short Term Debt	13,640	2,753	1,985	1,581	-	500	-	-	-	-	-
Short Term Investments	149,877	264,984	300,255	184,792	248,933	86,873	207,714	296,736	82,219	-	-
Temporary Equity Redeemable Noncontrolling Interests	-	-	-	-	-	0	0	0	0	-	-
Total Assets	376,420	468,127	588,120	342,942	391,839	217,779	263,914	324,975	106,122	51,828	4,290
Total Current Assets	295,080	384,621	523,273	272,992	321,489	172,190	260,553	324,597	106,026	51,808	4,242
Total Current Liabilities	78,916	105,786	82,901	36,743	39,979	27,646	9,675	9,709	2,724	1,524	1,302
Total Liab	249,780	188,513	125,781	52,161	52,982	39,915	10,178	9,875	2,940	62,845	8,017
Total Permanent Equity	-	-	-	-	-	0	0	0	0	-	-
Total Stockholder Equity	126,640	279,614	462,339	290,781	338,857	177,864	253,736	315,100	103,182	-11,017	-3,727
Treasury Stock	-	-	-	-	-	0	0	0	0	-	-

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31
Accounts Payable	6,871	11,296	12,799	11,945	17,368	16,543	12,301	17,355	7,118	5,190	5,106	8,079	7,963	5,155	6,420	6,168	3,719	6,193	6,545	6,098	14,711	5,539	5,243	2,204	2,778	4,463	3,235	1,896	1,445	1,853	1,703	794	440	569	577	1,402	606	-	-	-	121
Accumulated Other Comprehensive Income	-2,067	-2,959	-2,618	-1,892	-368	24	62	161	296	527	810	204	220	233	173	38	-340	-449	-505	-524	-151	-88	-114	-152	-183	35	193	51	-518	51	-66	-18	-100	-11	-	-11	-3,823	-	-	-	-
Additional Paid In Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Capital Lease Obligations	71,704	61,072	63,999	17,453	25,518	24,574	12,182	12,569	15,026	13,129	13,420	13,809	15,717	14,532	14,919	14,437	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Stock	10	9	9	9	9	9	8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital Surpluse	1,821,721	1,808,515	1,794,449	1,779,026	1,744,695	1,681,481	1,618,177	1,601,784	1,586,616	1,396,674	1,349,234	1,144,082	1,108,516	1,057,669	899,671	877,133	866,541	850,835	841,975	777,797	474,662	467,378	451,496	436,096	431,075	429,088	423,600	418,451	413,725	410,556	214,313	216,159	144,169	7,344	-	-	-	-	-	-	-
Cash	92,942	65,114	70,688	101,669	106,084	113,209	123,856	151,097	200,404	62,620	74,511	70,203	74,317	94,431	59,159	56,168	60,698	66,028	103,203	90,495	79,223	60,493	64,237	62,430	47,968	46,013	26,356	22,056	23,746	54,466	26,190	71,329	21,897	25,703	31,779	39,754	51,615	-	-	-	4,207
Cash And Short Term Investments	242,819	265,404	331,311	301,811	371,068	357,245	373,380	435,161	500,659	327,185	347,712	214,631	259,109	282,922	190,135	237,545	309,631	364,543	417,015	407,321	166,096	200,221	216,896	230,646	255,682	278,147	294,557	306,403	320,482	334,265	155,031	166,696	104,116	51,699	56,498	62,031	51,615	-	-	-	-
Common Stock	10	9	9	9	9	9	8	8	8	8	7	6	6	5	5	5	5	5	5	4	3	3	3	3	3	3	3	3	3	3	2	2	2	0	1	-	1	-	-	-	1
Common Stock Shares Outstanding	103,178	102,423	101,866	100,726	97,407	93,602	92,152	91,456	85,301	81,176	67,975	61,208	57,662	54,920	46,426	46,124	45,777	45,406	44,379	39,596	30,651	30,474	29,247	29,056	28,915	28,801	28,665	28,542	28,413	27,675	24,224	21,918	15,805	19,403	19,403	13,677	13,677	13,677	13,677	13,677	-
Common Stock Total Equity	10	9	9	9	9	9	8	8	8	8	7	6	6	5	5	5	5	5	5	4	3	3	3	3	3	3	3	3	3	3	2	2	2	0	1	-	1	-	-	-	-
Current Deferred Revenue	8,000	2,662	1,671	50,943	40,760	31,226	40,968	35,497	33,455	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Long Term Liab	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Good Will	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Intangible Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Inventory	1,586	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Liabilities And Stockholders Equity	376,420	368,316	436,121	397,280	468,127	449,923	456,791	529,637	588,120	405,532	428,111	299,547	342,942	364,785	274,144	324,726	391,839	442,940	492,707	473,108	217,779	229,693	244,155	241,738	263,914	284,417	300,814	312,978	324,975	340,379	161,102	169,817	106,122	54,120	58,503	62,866	51,828	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14,437	-	10,300	10,300	10,300	10,513	6,200	10,900	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Long Term Debt Total	-	-	-	-	-	-	-	-	-	-	-	-	244	85	141	196	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Debt	-34,878	-4,042	-6,689	-84,216	-77,813	-88,635	-111,674	-138,528	-185,378	-49,491	-61,091	-56,394	-58,600	-79,899	-44,240	-41,731	-60,698	-66,028	-103,203	-90,495	-79,223	-60,493	-64,237	-62,430	-47,968	-46,013	-26,356	-22,056	-23,746	-54,466	-26,190	-71,329	-21,897	-25,703	-31,779	-39,754	-51,615	-	-	-	-
Net Invested Capital	126,640	187,113	257,479	224,316	279,614	310,141	331,538	399,037	462,339	353,935	381,125	252,822	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Receivables	40,221	249	637	668	986	400	700	9,610	1,250	800	800	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Tangible Assets	126,640	187,113	257,479	224,316	279,614	310,141	331,538	399,037	462,339	353,935	381,125	252,822	290,781	318,442	232,279	283,934	338,857	403,054	452,499	439,184	177,864	205,956	221,144	233,134	253,736	270,202	290,245	303,834	315,100	333,748	149,255	166,094	103,182	51,543	-	-	-	-	-	-	-
Net Working Capital	216,164	210,802	281,296	212,827	278,835	283,347	303,495	380,113	440,372	303,377	327,303	197,697	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Current Assets Total	81,340	85,270	89,137	82,891	83,506	80,426	64,466	65,330	64,847	66,100	69,124	70,330	69,950	71,367	73,005	73,896	70,350	69,964	67,637	59,494	45,589	23,476	21,663	6,420	3,361	2,187	1,931	1,237	378	144	468	126	96	2,098	1,418	575	20	-	-	-	-
Non Current Liabilities Other	170,864	108,959	5,626	71,402	1,501	53,632	1,771	46,406	42,880	15,542	15,302	15,205	15,418	15,637	16,062	15,617	-	-	-	-	-	-	-	-	-	-	-	-	-	181	203	209	216	165	-	-	-	-	-	-	-
Non Current Liabilities Total	170,864	108,959	112,954	71,402	82,727	53,632	36,423	46,406	42,880	15,542	15,302	15,205	15,418	15,637	16,062	15,617	13,003	12,886	12,974	12,875	12,269	7,221	11,530	799	503	527	563	284	166	181	203	209	216	74,737	179	74,782	61,321	-	-	-	-
Non Currrent Assets Other	7,018	7,166	7,227	54,849	3,567	1,870	1,889	1,929	2,027	2,077	2,216	2,197	1,767	1,466	1,519	1,736	1,774	1,685	1,562	1,300	1,460	1,300	1,376	2,020	102	102	101	89	108	98	426	79	48	2,084	1,407	567	12	-	-	-	-
Noncontrolling Interest In Consolidated Entity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Other Assets	-	7,166	7,227	54,849	3,567	1,870	1,889	1,929	14,330	2,077	2,216	2,197	1,767	1,466	1,519	1,736	1,774	1,685	1,562	1,300	1,460	1,300	1,376	2,020	102	102	101	89	108	98	426	79	48	2,084	1,407	-	12	-	-	-	39
Other Current Assets	10,308	17,393	15,036	11,910	12,567	12,252	18,945	19,536	21,364	12,247	11,275	14,586	13,883	10,496	11,004	13,285	11,858	8,433	8,055	6,293	6,094	5,996	5,596	4,672	4,871	4,083	4,326	5,338	4,115	5,970	5,603	2,995	1,910	323	587	260	193	-	-	-	35
Other Current Liab	50,405	58,286	51,218	38,674	44,905	38,381	35,561	31,342	40,343	30,865	26,578	23,441	27,199	25,551	19,383	19,007	36,260	20,807	20,689	14,951	12,935	10,977	6,238	5,601	6,897	9,225	6,771	6,964	8,264	4,597	9,941	2,720	2,284	1,843	1,524	1,386	918	-	-	-	1,174
Other Liab	-	47,887	48,955	53,949	57,209	29,058	24,241	33,837	29,690	2,413	1,882	1,396	1,038	1,020	1,002	984	2,703	2,586	2,674	2,575	1,756	1,021	630	799	503	527	563	284	166	181	203	209	216	165	183	-	230	-	-	-	4
Other Stockholder Equity	1,821,721	1,808,515	1,794,449	1,779,026	1,744,695	1,681,481	1,618,177	1,601,784	1,586,616	1,396,674	1,349,234	1,144,082	1,108,516	1,057,669	899,671	877,133	866,541	850,835	841,975	777,797	474,662	467,378	451,496	436,096	431,075	429,088	423,600	418,451	413,725	410,556	214,313	216,159	144,169	7,344	84,477	5,239	1,865	-	-	-	-
Preferred Stock Total Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	74,572	74,572	-	61,091	-	-	-	6,711
Property Plant And Equipment Gross	-	-	-	-	-	-	62,577	63,401	62,820	64,023	66,908	68,133	68,183	69,901	71,486	72,160	68,576	68,279	66,075	58,194	44,129	22,176	20,287	4,400	3,259	2,085	1,830	1,148	270	46	42	47	48	14	11	8	8	-	-	-	-
Property Plant And Equipment Net	74,322	78,104	81,910	28,042	79,939	78,556	62,577	63,401	62,820	64,023	66,908	68,133	68,183	69,901	71,486	72,160	68,576	68,279	66,075	58,194	44,129	22,176	20,287	4,400	3,259	2,085	1,830	1,148	270	46	42	47	48	14	11	8	8	-	-	-	-
Property Plant Equipment	6,300	78,104	81,910	9,109	79,939	53,485	62,577	51,471	50,517	51,954	53,587	54,442	54,176	55,697	57,090	58,119	68,576	68,279	66,075	58,194	44,129	22,176	20,287	4,400	3,259	2,085	1,830	1,148	270	46	42	47	48	14	11	-	8	-	-	-	9
Retained Earnings	-1,693,024	-1,618,452	-1,534,361	-1,552,827	-1,464,722	-1,371,373	-1,286,709	-1,202,916	-1,124,581	-1,043,274	-968,926	-891,470	-817,961	-739,465	-667,570	-593,242	-527,349	-447,337	-388,976	-338,093	-296,650	-261,337	-230,241	-202,813	-177,159	-158,924	-133,551	-114,671	-98,110	-76,862	-64,994	-50,049	-40,889	-30,362	-28,255	-19,932	-12,883	-	-	-	-
Retained Earnings Total Equity	-1,693,024	-1,618,452	-1,534,361	-1,552,827	-1,464,722	-1,371,373	-1,286,709	-1,202,916	-1,124,581	-1,043,274	-968,926	-891,470	-817,961	-739,465	-667,570	-593,242	-527,349	-447,337	-388,976	-338,093	-296,650	-261,337	-230,241	-202,813	-177,159	-158,924	-133,551	-114,671	-98,110	-76,862	-64,994	-50,049	-40,889	-30,362	-	-	-	-	-	-	-
Short Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	643	-	-	10,300	10,300	500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short Long Term Debt Total	58,064	61,072	63,999	17,453	28,271	24,574	12,182	12,569	15,026	13,129	13,420	13,809	15,717	14,532	14,919	14,437	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short Term Debt	13,640	-	-	-	2,753	-	-	-	1,985	-	-	-	1,581	-	-	643	-	-	10,300	10,300	500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Short Term Investments	149,877	200,290	260,623	200,142	264,984	244,036	249,524	284,064	300,255	264,565	273,201	144,428	184,792	188,491	130,976	181,377	248,933	298,515	313,812	316,826	86,873	139,728	152,659	168,216	207,714	232,134	268,201	284,347	296,736	279,799	128,841	95,367	82,219	25,996	24,719	22,277	-	-	-	-	-
Temporary Equity Redeemable Noncontrolling Interests	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Total Assets	376,420	368,316	436,121	397,280	468,127	449,923	456,791	529,637	588,120	405,532	428,111	299,547	342,942	364,785	274,144	324,726	391,839	442,940	492,707	473,108	217,779	229,693	244,155	241,738	263,914	284,417	300,814	312,978	324,975	340,379	161,102	169,817	106,122	54,120	58,503	62,866	51,828	-	-	-	4,290
Total Current Assets	295,080	283,046	346,984	314,389	384,621	369,497	392,325	464,307	523,273	339,432	358,987	229,217	272,992	293,418	201,139	250,830	321,489	372,976	425,070	413,614	172,190	206,217	222,492	235,318	260,553	282,230	298,883	311,741	324,597	340,235	160,634	169,691	106,026	52,022	57,085	62,291	51,808	-	-	-	-
Total Current Liabilities	78,916	72,244	65,688	101,562	105,786	86,150	88,830	84,194	82,901	36,055	31,684	31,520	36,743	30,706	25,803	25,175	39,979	27,000	27,234	21,049	27,646	16,516	11,481	7,805	9,675	13,688	10,006	8,860	9,709	6,450	11,644	3,514	2,724	2,412	2,101	2,788	1,524	-	-	-	1,302
Total Liab	249,780	181,203	178,642	172,964	188,513	139,782	125,253	130,600	125,781	51,597	46,986	46,725	52,161	46,343	41,865	40,792	52,982	39,886	40,208	33,924	39,915	23,737	23,011	8,604	10,178	14,215	10,569	9,144	9,875	6,631	11,847	3,723	2,940	77,149	2,280	77,570	62,845	-	-	-	1,306
Total Permanent Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Total Stockholder Equity	126,640	187,113	257,479	224,316	279,614	310,141	331,538	399,037	462,339	353,935	381,125	252,822	290,781	318,442	232,279	283,934	338,857	403,054	452,499	439,184	177,864	205,956	221,144	233,134	253,736	270,202	290,245	303,834	315,100	333,748	149,255	166,094	103,182	-23,029	56,223	-14,704	-11,017	-	-	-	2,984
Treasury Stock	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-
Warrants	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	149,144	-	-	-	-	-	-	-

Cash Flow

Currency in USD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Begin Period Cash Flow	107,478	201,798	75,711	62,092	80,617	47,968	23,746	21,897	51,615	4,207
Capital Expenditures	4,193	10,580	4,513	5,733	35,925	20,232	3,020	290	46	3
Cash And Cash Equivalents Changes	-14,390	-94,320	126,087	13,619	-18,525	31,255	24,222	1,849	-29,718	-
Cash Flows Other Operating	14,164	4,182	-386	-11,073	9,126	816	-3,440	3,481	-1,283	-
Change In Cash	-14,390	-94,320	126,087	13,619	-18,525	31,255	24,222	1,849	-29,718	47,408
Change In Working Capital	-61,468	52,584	63,685	-4,148	15,003	7,201	-725	6,186	-3	1,094
Change Receivables	-39,235	264	-1,250	-	-	-	-	-	-	-
Change To Account Receivables	-39,235	264	-1,250	-1,250	-1,250	-1,250	0	0	0	-
Change To Inventory	-1,586	-	-	-	-	0	0	0	0	-
Change To Liabilities	-25,749	44,285	66,778	7,889	5,877	6,385	2,715	2,726	1,278	1,077
Change To Netincome	3,601	57,603	51,481	52,723	34,028	23,100	16,784	10,345	10,851	148
Change To Operating Activities	-	8,035	4,500	-8,361	16,961	5,038	-1,706	5,181	161	-
Depreciation	5,653	9,345	8,332	7,070	3,732	956	383	48	6	4
Dividends Paid	-	-	-	-	-	0	0	0	0	-
End Period Cash Flow	93,088	107,478	201,798	75,711	62,092	79,223	47,968	23,746	21,897	51,615
Exchange Rate Changes	-	-	-	-	-	-	-	-94	-	-
Free Cash Flow	-274,623	-231,102	-185,272	-241,359	-215,697	-107,734	-63,045	-37,446	-16,674	-5,969
Investments	112,384	32,838	-116,215	66,031	-160,364	120,141	86,761	-219,643	-83,317	-
Issuance Of Capital Stock	52,496	98,697	422,969	188,617	340,876	-	-	-	-	-
Net Borrowings	-	-254	-389	-486	-528	9,904	-528	-528	337	-
Net Income	-228,302	-340,141	-306,620	-290,976	-230,699	-119,491	-79,049	-57,221	-28,006	-8,773
Other Cashflows From Financing Activities	1,106	5,501	4,994	655	17,188	892	506	-4,208	13,818	53,377
Other Cashflows From Investing Activities	94,765	-	-	161	-160,364	-1,200	86,761	-194	-194	-
Other Non Cash Items	-40,151	3,825	2,493	732	-1,625	732	2,582	3,580	1,274	-4
Sale Purchase Of Stock	23,812	105,459	75,869	55,079	365,567	20,405	600	263,873	69,936	-
Stock Based Compensation	53,838	53,865	51,351	51,696	33,817	23,100	16,784	10,251	10,101	1,713
Total Cash From Financing Activities	53,084	103,944	427,574	188,786	357,536	20,048	506	259,226	70,273	53,377
Total Cash From Operating Activities	-270,430	-220,522	-180,759	-235,626	-179,772	-87,502	-60,025	-37,156	-16,628	-5,966
Total Cashflows From Investing Activities	202,956	22,258	-120,728	60,459	-196,289	98,709	83,741	-220,127	-83,363	-

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31
Begin Period Cash Flow	66,460	72,034	103,015	107,478	114,603	125,250	152,491	201,798	64,014	75,905	71,597	75,711	95,825	60,553	57,562	62,092	67,422	104,597	91,889	80,617	60,493	64,237	62,430	47,968	46,013	26,356	22,056	23,746	54,466	26,190	71,329	21,897	25,703	31,779	39,754	51,615	15,690	17,379	39,754	51,615
Capital Expenditures	37	132	1,419	2,605	2,466	3,856	2,061	2,197	601	503	2,076	1,333	2,712	1,487	738	796	4,169	4,499	7,449	19,808	9,697	6,194	3,135	1,206	995	386	748	891	271	14	5	5	36	5	8	13	3	0	2	1
Cash And Cash Equivalents Changes	26,628	-5,574	-30,981	-4,463	-7,125	-10,647	-27,241	-49,307	137,784	-11,891	4,308	-4,114	-20,114	35,272	2,991	-4,530	-5,330	-37,175	12,708	11,272	18,730	-3,744	1,807	14,462	1,955	19,657	4,300	-1,690	-30,720	28,276	-45,139	49,432	-	-	-	-	-	-	-	-
Cash Flows Other Operating	14,467	349	-1,833	1,181	-828	5,597	2,738	-3,325	-2,498	875	3,637	-2,400	-66	1,574	1,761	-14,342	11,893	-3,359	-1,709	2,301	537	1,415	-315	-821	-2,841	1,523	-154	-1,968	6,045	-3,726	2,274	-1,112	-	-	-	-	-	-	-	-
Change In Cash	26,628	-5,574	-30,981	-4,463	-7,125	-10,647	-27,241	-49,307	137,784	-11,891	4,308	-4,114	-20,114	35,272	2,991	-4,530	-5,330	-37,175	12,708	11,272	18,730	-3,744	1,807	14,462	1,955	19,657	4,300	-1,690	-30,720	28,276	-45,139	49,432	-3,806	-6,076	-7,975	39,754	35,925	-1,689	-22,375	-11,861
Change In Working Capital	2,135	707	-50,828	-13,482	41,329	8,666	5,196	-2,607	62,742	5,287	4,209	-8,553	5,675	4,581	3,015	-17,419	12,091	304	3,181	-573	3,875	4,469	1,091	-2,234	-4,529	3,879	1,922	-1,997	4,999	-4,110	5,606	-309	-482	480	-2,119	2,118	371	507	-583	799
Change Receivables	-39,972	388	31	318	-986	-	9,610	-8,360	-1,250	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change To Account Receivables	-39,972	388	31	318	-986	1,250	9,610	-8,360	-1,262	12	-1,250	-1,250	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Change To Inventory	-1,586	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
Change To Liabilities	32,185	2,718	-46,298	-14,354	38,757	3,589	-9,069	9,451	66,847	4,778	942	-5,789	5,937	3,775	1,254	-3,077	198	3,663	4,890	-2,874	3,338	3,054	1,406	-1,413	-1,688	2,356	2,076	-29	-1,025	-384	3,332	803	1,356	572	354	-	1,077	-	-	-
Change To Netincome	11,363	14,023	-36,120	14,335	15,240	13,762	14,680	12,268	11,541	13,255	14,041	12,644	12,174	12,952	15,328	12,269	9,553	9,337	8,060	7,078	6,097	6,000	5,656	5,347	1,656	5,264	5,098	4,766	3,058	2,234	2,570	2,483	11,375	-	-	-	148	-	-	-
Change To Operating Activities	-	1,695	-1,120	-8,687	3,558	9,682	4,655	-9,860	839	5,072	6,552	-7,963	2,989	5,703	3,038	-20,091	14,165	-19	1,269	1,546	5,038	4,723	372	-519	-1,706	213	477	-	5,181	-	-	-	161	-	-	-	-	-	-	-
Depreciation	1,255	1,369	1,438	1,591	2,488	2,317	2,318	2,222	2,157	2,173	2,053	1,949	1,896	1,789	1,737	1,648	1,478	1,190	731	333	278	250	222	206	173	131	64	15	27	10	5	6	2	2	-3	5	1	1	1	1
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	-	-	-	-
End Period Cash Flow	93,088	66,460	72,034	103,015	107,478	114,603	125,250	152,491	201,798	64,014	75,905	71,597	75,711	95,825	60,553	57,562	62,092	67,422	104,597	91,889	79,223	60,493	64,237	62,430	47,968	46,013	26,356	22,056	23,746	54,466	26,190	71,329	21,897	25,703	31,779	39,754	51,615	15,690	17,379	39,754
Exchange Rate Changes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38	-42	-94	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow	-56,917	-65,189	-65,383	-87,134	-36,735	-62,834	-63,638	-67,895	-4,721	-53,462	-58,712	-68,377	-61,402	-53,634	-55,327	-70,996	-61,588	-52,596	-46,883	-54,630	-34,635	-26,423	-23,436	-23,240	-22,159	-15,968	-11,536	-13,382	-11,663	-12,914	-6,242	-6,627	-4,993	-4,097	2,137	-9,721	-2,489	-1,689	1,127	-2,918
Investments	51,255	59,829	31,826	62,820	-21,858	5,050	33,950	15,696	-36,291	8,065	-128,295	40,306	3,839	-57,095	50,895	68,392	50,237	15,936	3,572	-230,109	52,667	12,809	15,437	39,228	23,783	35,422	15,804	11,752	-304,344	132,516	-34,387	-13,428	-83,317	-	-	-	-	-	-	-
Issuance Of Capital Stock	31,980	0	-23	20,539	49,958	46,357	-75	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Borrowings	-	-206	-126	-64	-62	-62	-64	-66	-100	-92	-107	-90	-141	-110	-137	-98	-132	-124	-171	-101	3,689	-4,655	10,584	286	-528	-	-	-	-528	-	-	-	337	-	-	-	-	-	-	-
Net Income	-74,572	-84,091	18,466	-88,105	-93,349	-84,664	-83,793	-78,335	-81,307	-74,348	-77,456	-73,509	-78,496	-71,895	-74,328	-66,257	-80,012	-58,361	-50,883	-41,443	-35,313	-31,096	-27,428	-25,654	-18,235	-25,373	-18,880	-16,561	-21,248	-11,868	-14,945	-9,160	-10,527	-5,919	8,372	-19,932	-3,556	-2,536	4,368	-7,049
Other Cashflows From Financing Activities	432	-8	1,306	-624	1,572	842	2,586	501	3,273	47	1,904	-230	2,491	158	-166	-1,828	6,153	-391	8,604	2,822	748	-10	9,806	-326	331	199	-6	-18	185	117	-4,510	-13,433	58,086	-548	-59,063	71,798	38,414	1	1,492	13,471
Other Cashflows From Investing Activities	-	-	94,765	-	-	-	-	-	-	-	-	40,306	66,192	65	96	68,392	-160,364	0	0	0	-1,200	0	0	-1,200	-1,200	0	0	0	285,196	-285,390	0	0	-194	0	-	-	-	-	-	-
Other Non Cash Items	2,939	2,935	-47,157	1,132	1,235	941	895	754	784	674	610	425	161	1,226	-214	-441	-529	-481	-462	-153	125	148	158	301	-229	513	970	1,328	1,866	834	522	358	277	861	-2,643	-10,104	-1	-1	-17	-5,736
Sale Purchase Of Stock	1,844	47	1,286	20,635	51,530	47,199	2,524	4,206	14,417	34,046	1,799	25,607	37,590	5,183	9,559	2,747	6,163	3,671	56,257	299,476	704	9,880	9,821	0	350	221	15	14	244	194,184	-42	69,487	56,455	0	-	-	-	-	-	-
Stock Based Compensation	11,363	14,023	14,117	14,335	14,028	13,762	13,807	12,268	11,504	13,255	13,948	12,644	12,074	12,152	15,201	12,269	9,553	9,251	7,999	7,014	6,097	6,000	5,656	5,347	1,656	5,268	5,136	4,724	2,964	2,234	2,570	2,483	5,773	484	-1,478	5,322	696	340	-2,640	3,317
Total Cash From Financing Activities	32,290	-214	1,157	19,851	51,468	47,137	2,447	2,892	178,796	33,506	191,315	23,957	37,449	145,936	7,327	-1,926	6,021	-515	56,019	296,011	698	9,870	9,806	-326	331	199	-6	-18	185	194,064	-4,510	69,487	58,086	-548	-59,154	71,889	38,414	-	1,492	13,471
Total Cash From Operating Activities	-56,880	-65,057	-63,964	-84,529	-34,269	-58,978	-61,577	-65,698	-4,120	-52,959	-56,636	-67,044	-58,690	-52,147	-54,589	-70,200	-57,419	-48,097	-39,434	-34,822	-24,938	-20,229	-20,301	-22,034	-21,164	-15,582	-10,788	-12,491	-11,392	-12,900	-6,242	-6,622	-4,957	-4,092	2,129	-9,708	-2,489	-1,689	1,129	-2,917
Total Cashflows From Investing Activities	51,218	59,697	31,826	60,215	-24,324	1,194	31,889	13,499	-36,892	7,562	-130,371	38,973	1,127	-58,517	50,253	67,596	46,068	11,437	-3,877	-249,917	42,970	6,615	12,302	36,822	22,788	35,036	15,056	10,861	-19,419	-152,888	-34,387	-13,433	-83,363	-26,428	-	-	-	-	-	-

Income Statement

Currency in USD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cost Of Revenue	-	-	-	-	0	0	0	0	0	-
Depreciation And Amortization	-50,237	9,345	8,332	7,070	3,732	956	383	48	6	4
Ebit	-280,513	-340,095	-317,384	-302,751	-230,743	-119,505	-79,039	-57,230	-28,031	-8,603
Ebitda	-330,750	-340,462	-309,052	-295,681	-227,011	-118,549	-78,656	-57,182	-28,025	-8,599
Gross Profit	63,573	20,340	-	-	0	0	0	0	0	-
Income Before Tax	-228,290	-340,095	-306,605	-290,964	-230,743	-119,505	-79,039	-57,230	-28,031	-8,603
Income Tax Expense	12	46	15	12	-44	-14	10	-9	-25	170
Interest Expense	1,986	9,712	10,779	11,787	0	0	0	0	0	0
Interest Income	1,986	-	2,447	4,717	6,368	2,027	2,203	1,218	-	-
Net Income	-228,302	-340,141	-306,620	-290,976	-230,699	-119,491	-79,049	-57,221	-28,006	-8,773
Net Income Applicable To Common Shares	-228,302	-340,141	-306,620	-290,976	-230,699	-119,491	-79,049	-57,221	-28,006	-
Net Income From Continuing Ops	-228,302	-340,141	-306,620	-290,976	-230,699	-119,491	-79,049	-57,221	-28,006	-
Net Interest Income	1,986	367	2,447	4,717	6,368	2,027	2,203	-	-	-
Non Operating Income Net Other	52,223	367	2,447	4,717	6,368	2,027	2,203	1,218	125	-
Operating Income	-280,513	-340,462	-309,052	-295,681	-237,111	-121,532	-81,242	-58,448	-28,156	-8,615
Other Operating Expenses	344,086	360,802	309,052	295,681	237,111	121,532	81,242	58,448	28,156	8,615
Reconciled Depreciation	5,653	9,345	8,332	7,070	3,732	956	-	-	-	-
Research Development	272,533	282,001	244,650	216,097	167,457	81,206	56,514	41,618	15,446	4,859
Selling General Administrative	71,553	78,801	64,402	79,584	69,654	40,326	24,728	16,830	12,710	3,756
Tax Provision	12	46	15	12	-44	-14	10	-9	-	-
Total Operating Expenses	344,086	360,802	309,052	295,681	237,111	121,532	81,242	58,448	28,156	8,615
Total Other Income Expense Net	52,223	367	2,447	4,717	6,368	2,027	2,203	1,218	125	12
Total Revenue	63,573	20,340	0	0	0	0	0	0	0	-

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31
Cost Of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Depreciation And Amortization	1,255	1,369	-48,799	1,591	2,488	2,317	2,318	2,222	2,157	2,173	2,053	1,949	1,896	1,789	1,737	1,648	1,478	1,190	731	333	278	250	222	206	173	131	64	15	27	10	5	6	2	2	-3	5	1	1	1	1
Discontinued Operations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Ebit	-72,577	-84,622	-32,132	-88,220	-93,319	-84,664	-83,777	-78,335	-81,299	-74,342	-77,455	-73,509	-78,484	-71,895	-74,328	-66,257	-80,059	-58,361	-50,880	-41,443	-35,329	-31,096	-27,428	-25,652	-18,235	-25,366	-18,880	-16,558	-21,248	-11,879	-14,945	-9,158	-10,530	-5,919	-4,511	-7,071	-3,413	-2,549	-1,357	-1,284
Ebitda	-75,539	-83,253	-80,931	-86,629	-90,831	-82,347	-81,459	-76,113	-79,142	-72,169	-75,402	-71,560	-76,588	-70,106	-72,591	-64,609	-78,581	-57,171	-50,149	-41,110	-35,051	-30,846	-27,206	-25,446	-18,062	-25,235	-18,816	-16,543	-21,221	-11,869	-14,940	-9,152	-10,528	-5,917	-4,514	-7,066	-3,412	-2,548	-1,356	-1,283
Effect Of Accounting Charges	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Extraordinary Items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Gross Profit	221	4,459	51,579	7,314	7,548	5,370	3,870	3,552	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Income Before Tax	-74,570	-84,081	18,466	-88,105	-93,319	-84,664	-83,777	-78,335	-81,299	-74,342	-77,455	-73,509	-78,484	-71,895	-74,328	-66,257	-80,059	-58,361	-50,880	-41,443	-35,329	-31,096	-27,428	-25,652	-18,235	-25,366	-18,880	-16,558	-21,248	-11,879	-14,945	-9,158	-10,530	-5,919	-4,511	-7,071	-3,413	-2,549	-1,357	-1,284
Income Tax Expense	2	10	-361	-115	30	-	16	8	8	6	1	-	12	-	-	-	-47	-3	3	0	-16	0	-2	2	3	7	-3	3	4	-11	-2	2	-3	-22	0	-22	143	-13	26	14
Interest Expense	969	541	361	115	-	-	-	-	-	-	-	-	115	115	115	115	128	128	128	128	200	100	100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Interest Income	-	-	-	-	-	-	-	-	398	364	497	1,188	1,215	661	1,207	1,634	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Net Income	-74,572	-84,091	18,466	-87,990	-93,349	-84,664	-83,793	-78,335	-81,307	-74,348	-77,456	-73,509	-78,496	-71,895	-74,328	-66,257	-80,012	-58,361	-50,883	-41,443	-35,313	-31,096	-27,428	-25,654	-18,235	-25,373	-18,880	-16,561	-21,248	-11,868	-14,945	-9,160	-10,527	-5,919	-4,511	-7,049	-3,556	-2,536	-1,383	-1,298
Net Income Applicable To Common Shares	-74,572	-84,091	18,466	-88,105	-93,349	-84,664	-83,793	-78,335	-81,307	-74,348	-77,456	-73,509	-78,496	-71,895	-74,328	-66,257	-80,012	-58,361	-50,883	-41,443	-35,313	-31,096	-27,428	-25,654	-18,235	-25,373	-18,880	-16,561	-21,248	-11,868	-14,945	-9,160	-28,006	-5,919	0	0	0	0	0	-
Net Income From Continuing Ops	-74,572	-84,091	18,466	-88,105	-93,349	-84,664	-83,793	-78,335	-81,307	-74,348	-77,456	-73,509	-78,496	-71,895	-74,328	-66,257	-80,012	-58,361	-50,883	-41,443	-35,313	-31,096	-27,428	-25,654	-18,235	-25,373	-18,880	-16,561	-21,248	-11,868	-14,945	-9,160	-28,006	-5,919	0	0	0	0	0	-
Net Interest Income	969	541	361	115	84	148	225	-90	398	364	497	1,188	1,215	661	1,207	1,634	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non Operating Income Net Other	969	541	50,598	115	84	148	225	-90	398	364	497	1,188	1,215	661	1,207	1,634	1,757	1,859	1,743	1,009	473	564	481	509	519	576	605	503	522	380	163	153	-	19	-	-	-	-	-	-
Non Recurring	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-4,500	0	0	0	0	0	0	0	0	-
Operating Income	-75,539	-84,622	-32,132	-88,220	-93,319	-84,812	-84,002	-78,245	-81,697	-74,706	-77,952	-74,697	-79,699	-72,556	-75,535	-67,891	-81,816	-60,220	-52,623	-42,452	-35,802	-31,660	-27,909	-26,161	-18,754	-25,942	-19,485	-17,061	-21,770	-12,259	-15,108	-9,311	-10,596	-5,949	-4,534	-7,077	-3,417	-2,552	-1,361	-1,286
Other Items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-
Other Operating Expenses	75,760	89,081	83,711	95,534	100,951	90,182	87,872	81,797	81,697	74,706	77,952	74,697	79,699	72,556	75,535	67,891	81,816	60,220	52,623	42,452	35,802	31,660	27,909	26,161	18,754	25,942	19,485	17,061	26,270	12,259	10,608	9,311	10,596	5,949	4,534	7,077	3,417	2,552	1,361	1,286
Reconciled Depreciation	1,255	1,369	1,438	1,591	2,488	2,317	2,318	2,222	2,157	2,173	2,053	1,949	1,896	1,789	1,737	1,648	1,478	1,190	731	333	278	250	222	206	173	131	64	15	27	10	5	6	2	2	-3	5	1	1	1	1
Research Development	62,515	70,157	64,898	74,963	79,134	70,333	68,475	64,059	65,554	59,877	61,560	57,659	61,640	53,538	52,251	48,668	62,255	43,355	33,387	28,460	24,771	20,598	18,296	17,541	13,474	18,802	12,991	11,247	20,731	8,113	7,007	5,767	5,048	4,241	3,176	2,981	2,252	1,684	569	354
Selling General Administrative	13,245	18,924	18,813	20,571	21,817	19,849	19,397	17,738	16,143	14,829	16,392	17,038	18,059	19,018	23,284	19,223	19,561	16,865	19,236	13,992	11,031	11,062	9,613	8,620	5,280	7,140	6,494	5,814	5,539	4,146	3,601	3,544	5,548	1,708	1,358	4,096	1,165	868	792	932
Tax Provision	2	10	0	0	30	0	16	-	8	6	1	-	12	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Operating Expenses	75,760	89,081	83,711	95,534	100,951	90,182	87,872	81,797	81,697	74,706	77,952	74,697	79,699	72,556	75,535	67,891	81,816	60,220	52,623	42,452	35,802	31,660	27,909	26,161	18,754	25,942	19,485	17,061	26,270	12,259	10,608	9,311	10,596	5,949	4,534	7,077	3,417	2,552	1,361	1,286
Total Other Income Expense Net	969	541	50,598	115	84	148	225	-90	398	364	497	1,188	1,215	661	1,207	1,634	1,757	1,859	1,743	1,009	473	564	481	509	519	576	605	503	522	380	-4,500	153	66	30	23	6	4	3	4	2
Total Revenue	221	4,459	51,579	7,314	7,548	5,370	3,870	3,552	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-

Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue	63,573
Cost of Revenue	--
Gross Profit	63,573	63,573

Operating Income (+$)
Gross Profit	63,573
Operating Expense	-344,086
Operating Income	-280,513	-280,513

Operating Expense (+$)
Research Development	272,533
Selling General Administrative	71,553
Selling And Marketing Expenses	-
Operating Expense	344,086	344,086

Net Interest Income (+$)
Interest Income	1,986
Interest Expense	-1,986
Other Finance Cost	-1,986
Net Interest Income	1,986

Pretax Income (+$)
Operating Income	-280,513
Net Interest Income	1,986
Other Non-Operating Income Expenses	52,223
Income Before Tax (EBT)	-228,290	-332,736 EBIT - interestExpense = -282,499 -228,290 -226,316
Interest Expense	1,986
Earnings Before Interest and Taxes (EBIT)	-280,513	-226,304
Earnings Before Interest and Taxes (EBITDA)	-330,750

After tax Income (+$)
Income Before Tax	-228,290
Tax Provision	-12
Net Income From Continuing Ops	-228,302	-228,302
Net Income	-228,302
Net Income Applicable To Common Shares	-228,302

Non-recurring Events
Discontinued Operations	-
Extraordinary Items	-
Effect of Accounting Charges	-
Other Items	-
Non Recurring	-
Other Operating Expenses	344,086
Total Other Income/Expenses Net	52,223	-54,209

Technicals of Atara Biotherapeutics Inc

1. Trend Indicators

1.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Directionalities and relatives.

Moving Average	Amount of candles	Trend	Price +/-	vs. MA 50	vs. MA 100	vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Atara Biotherapeutics Inc Daily Moving Averages Chart

1.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Let's take a look of the Moving Average Convergence/Divergence (MACD) of Atara Biotherapeutics Inc:

Atara Biotherapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart

1.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).

The ADX helps you determine the strength of a trend. Let's take a look of the ADX of Atara Biotherapeutics Inc:

The ADX is .

Atara Biotherapeutics Inc Buy, Hold or Sell?

Let's analyse Atara Biotherapeutics Inc together

Get notifications about Atara Biotherapeutics Inc

Quick analysis of Atara Biotherapeutics Inc (30 sec.)

1. Valuation of Atara Biotherapeutics Inc (5 min.)

$1.88

$1.23

2. Growth of Atara Biotherapeutics Inc (5 min.)

Is Atara Biotherapeutics Inc growing?

How much money is Atara Biotherapeutics Inc making?

How much money comes from the company's main activities?

3. Financial Health of Atara Biotherapeutics Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Fundamentals of Atara Biotherapeutics Inc

Financial Health

1.1. Profitability of Atara Biotherapeutics Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Atara Biotherapeutics Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Atara Biotherapeutics Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Atara Biotherapeutics Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Atara Biotherapeutics Inc

2. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

2.2. Price Earnings to Growth Ratio

Trends

Compared to industry (Biotechnology)

2. Book Value per Share

2.3. Price to Book Ratio

Trends

Compared to industry (Biotechnology)

Atara Biotherapeutics Inc
Buy, Hold or Sell?